Literature DB >> 16493391

Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy.

J P Cata1, H R Weng, B N Lee, J M Reuben, P M Dougherty.   

Abstract

Pain arises from numerous causes in cancer patients. Well known to cancer care providers, but perhaps less well so to others, is that the main causes of pain in cancer patients in fact arise due to cancer treatments more so than the disease itself. In this paper clinical and laboratory findings on the characteristics of chemotherapy-induced neuropathic pain are reviewed and a scheme for the underlying mechanisms is outlined.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16493391

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN： 0375-9393            Impact factor:   3.051


  80 in total

1.  Novel small molecule α9α10 nicotinic receptor antagonist prevents and reverses chemotherapy-evoked neuropathic pain in rats.

Authors:  Elzbieta P Wala; Peter A Crooks; J Michael McIntosh; Joseph R Holtman
Journal:  Anesth Analg       Date:  2012-05-18       Impact factor: 5.108

2.  Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats.

Authors:  Annemarie Ledeboer; Brian M Jekich; Evan M Sloane; John H Mahoney; Stephen J Langer; Erin D Milligan; David Martin; Steven F Maier; Kirk W Johnson; Leslie A Leinwand; Raymond A Chavez; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2006-12-15       Impact factor: 7.217

3.  Toll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral neuropathy.

Authors:  Yan Li; Haijun Zhang; Hongmei Zhang; Alyssa K Kosturakis; Abdul Basit Jawad; Patrick M Dougherty
Journal:  J Pain       Date:  2014-04-19       Impact factor: 5.820

4.  MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy.

Authors:  Yan Li; Hongmei Zhang; Alyssa K Kosturakis; Ryan M Cassidy; Haijun Zhang; Ross M Kennamer-Chapman; Abdul Basit Jawad; Cecilia M Colomand; Daniel S Harrison; Patrick M Dougherty
Journal:  Brain Behav Immun       Date:  2015-06-09       Impact factor: 7.217

5.  Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.

Authors:  E J Rahn; A Makriyannis; A G Hohmann
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

6.  Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.

Authors:  Richard A Slivicki; Shahin A Saberi; Vishakh Iyer; V Kiran Vemuri; Alexandros Makriyannis; Andrea G Hohmann
Journal:  J Pharmacol Exp Ther       Date:  2018-10-01       Impact factor: 4.030

7.  Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats.

Authors:  Elizabeth J Rahn; Alexander M Zvonok; Ganesh A Thakur; Atmaram D Khanolkar; Alexandros Makriyannis; Andrea G Hohmann
Journal:  J Pharmacol Exp Ther       Date:  2008-07-29       Impact factor: 4.030

8.  Persistent hyperalgesia in the cisplatin-treated mouse as defined by threshold measures, the conditioned place preference paradigm, and changes in dorsal root ganglia activated transcription factor 3: the effects of gabapentin, ketorolac, and etanercept.

Authors:  Hue Jung Park; Jennifer A Stokes; Elaine Pirie; James Skahen; Yuri Shtaerman; Tony L Yaksh
Journal:  Anesth Analg       Date:  2012-12-07       Impact factor: 5.108

9.  Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine.

Authors:  Jessica A Boyette-Davis; Juan P Cata; Larry C Driver; Diane M Novy; Brian M Bruel; Deidre L Mooring; Gwen Wendelschafer-Crabb; William R Kennedy; Patrick M Dougherty
Journal:  Cancer Chemother Pharmacol       Date:  2012-12-11       Impact factor: 3.333

Review 10.  Review of the complications associated with treatment of oropharyngeal cancer: a guide for the dental practitioner.

Authors:  Lena Turner; Muralidhar Mupparapu; Sunday O Akintoye
Journal:  Quintessence Int       Date:  2013-03       Impact factor: 1.677
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.